Posts by: Patricia Inacio PhD

Patricia Inacio PhD

June 8, 2017

Early Data from Immunotherapy Studies in Advanced Cancer Patient Show Promise, Parker Institute Reports

News

Researchers at the Parker Institute for Cancer Immunotherapy have shown that the combination of Imfinzi (durvalumab) and tremelimumab, two immune checkpoint inhibitors, has a manageable safety profile and promising evidence of clinical ... Read more

June 6, 2017

Insights into Yervoy and Target Molecule Has Potential for Improved Immunotherapies

News

Researchers unraveled the structure of interaction between immunotherapy drug Yervoy (ipilimumab) with its target molecule, and were able to build a three-dimensional model of the binding between the two. These results will aid ... Read more

June 5, 2017June 5, 2017

Genome Profiling May Help Predict Response to Keytruda in Head-Neck Cancer Patients

News

Profiling the genome of patients with head and neck squamous cell carcinoma (HNSCC) for mutations and interferon (IFN)-gamma-induced gene expression may independently predict patients’ response to immunotherapy with Keytruda (pembrolizumab), ... Read more

May 18, 2017May 18, 2017

Vaccines Based on Immunotherapies Being Tested in Phase 2 Trials in Brain Cancer

News

Immunomic Therapeutics has entered an exclusive licensing agreement with Annias Immunotherapeutics for the rights to use Annia’s intellectual property regarding an immunotherapy based on antigens of cytomegalovirus (CMV). Both companies are developing new approaches for generating vaccines ... Read more

March 20, 2017March 20, 2017

Protein Known as Moesin Seen as Potential Target for Anti-Cancer Therapy in Early Study

News

In a preclinical study, researchers discovered that the protein moesin plays a key role in shutting down the immune response against cancer cells. These results support moesin as a potential ... Read more

August 18, 2016August 18, 2016

Researchers Discover How Immune System T-Cells Determine Function

News

Scientists have partially unlocked the mystery behind T-cell identification by showing how individual T-cells determine what their functions will be. The study “Tcf1 and Lef1 transcription factors establish CD8+ T ... Read more

July 20, 2016July 20, 2016

Top Compounds to Boost Cancer Immunotherapies Identified by Insilico Medicine

News

Insilico Medicine has developed tools to analyze the molecular differences between patients who respond and fail to clinically approved immunotherapies based on checkpoints inhibitors. Immunotherapy has been successfully used to fight several types ... Read more

July 18, 2016July 18, 2016

Immunotherapy, Chemotherapy Combo Zeroes in on Mouse Tumors

News

The chemotherapy drug cyclophosphamide combined with the immunotherapy motolimod enhances the immune system’s fight against tumors in mice with advanced and metastatic cancers, according to the study “Definitive activation of endogenous antitumor ... Read more

July 8, 2016July 8, 2016

Colorectal Cancers Could Respond Better to Immunotherapy with Specific Immune Cells, Study Reports

News

A specific population of immune regulatory T cells (Treg) expressing low levels of the FOXP3 transcription factor, are triggered by intestinal bacteria and initiate anti-tumour immune responses in colorectal cancers according ... Read more

July 6, 2016July 6, 2016

Certain Metastatic Colorectal Cancer Responsive to Combined Immunotherapy

News

Combining anti-PD-L1 immunotherapy with an MEK inhibitor significantly increases treatment response in patients with microsatellite-stable metastatic colorectal cancer, according to results from a Phase 1b trial presented at the recent European Society for Medical ... Read more